Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Operating Cash Flow

Cash generated by the company's core business operations during the period.

Benitec Biopharma Inc.NASDAQ: BNTC

Operating Cash Flow · Q3 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q3 FY2026 operating cash flow of $4.91M (cash outflow) rose 59.2% year over year, ahead of the +10.2% change in trailing-twelve-month operating cash flow. Sequentially, it rose 30.1% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +59.2% holds above the trailing-twelve-month pace of +10.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.91M+30.1% QoQ
Last fiscal yearJun 2025
-$23.59M+21.6% YoY
LTMMar 2026
-$20.57M+10.2% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.2%——
1 year+21.6%——
3-year CAGR+14.1%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(23.59M) USD
Year-over-year change
-21.6%

Operating Cash Flow vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's LTM Mar 2026 operating cash flow of $20.57M is the 8th largest of the 10 companies compared; the peer median is $81.94M.
  • Its year-over-year change of +10.2% is the 6th highest of 10, against a peer median of +13.3%.
  • Over three fiscal years its annual growth of +14.1% compares with a peer median of +1.5%.
BNTC Competitors Peer median
Operating Cash Flow for BNTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$273.32M +13.3%+36.2%295.2%
SLDBSolid Biosciences Inc.LTM Mar 2026$171.67M +60.9%+16.8%—
QSIQuantum-Si incorporatedLTM Mar 2026$94.2M +3.8%+1.5%5086.4%
PRTCPureTech Health plcFY2025$85.33M -36.5%-21.9%1831.5%
NGNENeurogene Inc.LTM Mar 2026$81.94M +17.5%+13.5%—
OCGNOcugen, Inc.LTM Mar 2026$59.4M +16.7%-1.8%1330.4%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$22.11M -0.4%—149.6%
BNTCBenitec Biopharma Inc.LTM Mar 2026$20.57M +10.2%+14.1%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$20.05M -46.3%-8.4%—
XOMAXOMA Royalty Corp.LTM Mar 2026$6.63M +199.3%—18.3%
Peer median (excluding BNTC) $81.94M+13.3%+1.5%812.8%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Depreciation & Amortization424K392K381K343K396K
Deferred Income Tax00(714K)00
Stock-Based Compensation634K870K452K830K17.43M
Change in Working Capital8K1.04M714K1.17M(2.73M)
Accounts Receivables28K1K(50K)(176K)197K
Inventory(83K)(1.09M)(1.31M)00
Accounts Payables55K1.09M1.36M0(2.38M)
Other Working Capital8K1.04M714K1.35M(548K)
Other Non-Cash Items(16K)10K717K1K(764K)
Operating Cash Flow(12.83M)(15.9M)(18.01M)(19.4M)(23.59M)
Capital Expenditures(221K)(13K)(1K)(179K)(18K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(221K)(13K)(1K)(179K)(18K)
Debt Repayment00000
Common Stock Issued25.75M017.88M70.88M70.49M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.23M)0(1.87M)(2.85M)0
Financing Cash Flow22.52M016.02M68.03M70.49M
Effect of Forex Changes499K204K412K(8K)49K
Net Change in Cash9.97M(15.71M)(1.59M)48.44M46.93M
Free Cash Flow(13.05M)(15.91M)(18.01M)(19.58M)(23.61M)

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.